Beta Bionics (NASDAQ:BBNX) Shares Down 7.7% – Time to Sell?

Beta Bionics, Inc. (NASDAQ:BBNX) fell 7.7% during trading on Tuesday . The stock traded as low as $13.51 and last traded at $13.2770. 127,444 shares traded hands during trading, a decline of 89% from the average session volume of 1,130,836 shares. The stock had previously closed at $14.38.

Analyst Ratings Changes

Several brokerages have commented on BBNX. Weiss Ratings downgraded Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Stifel Nicolaus lowered their target price on Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Lake Street Capital set a $20.00 target price on Beta Bionics in a research note on Wednesday, February 18th. Bank of America lowered their target price on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research note on Monday, May 18th. Finally, The Goldman Sachs Group lowered their target price on Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.70.

Beta Bionics Stock Down 4.5%

The company has a 50 day moving average price of $11.40 and a 200-day moving average price of $16.47. The company has a market cap of $612.03 million, a price-to-earnings ratio of -9.10 and a beta of 3.40.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04. The company had revenue of $27.63 million during the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. On average, analysts forecast that Beta Bionics, Inc. will post -2.22 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Mark Hopman sold 5,329 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total value of $67,198.69. Following the completion of the sale, the insider directly owned 130,887 shares in the company, valued at $1,650,485.07. This represents a 3.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Christy Jones sold 2,811 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $14.00, for a total value of $39,354.00. Following the completion of the sale, the director owned 27,400 shares of the company’s stock, valued at $383,600. The trade was a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 27,687 shares of company stock valued at $343,586 over the last ninety days. 5.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Beta Bionics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its position in Beta Bionics by 3,238.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 205,955 shares of the company’s stock valued at $4,092,000 after purchasing an additional 199,785 shares during the period. Pura Vida Investments LLC increased its position in Beta Bionics by 11,150.0% during the 3rd quarter. Pura Vida Investments LLC now owns 281,250 shares of the company’s stock valued at $5,588,000 after purchasing an additional 278,750 shares during the period. SG Americas Securities LLC acquired a new stake in Beta Bionics during the 4th quarter valued at approximately $4,579,000. Farallon Capital Management LLC increased its position in Beta Bionics by 2.6% during the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock valued at $85,718,000 after purchasing an additional 110,000 shares during the period. Finally, First Eagle Investment Management LLC acquired a new stake in Beta Bionics during the 3rd quarter valued at approximately $4,634,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.